NASDAQ:TSRO - TESARO Stock Price, News, & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Sign in or create an account to add this stock to your watchlist.
Previous Close$74.96
Today's Range$74.94 - $74.97
52-Week Range$23.41 - $75.16
Volume1.19 million shs
Average Volume1.97 million shs
Market Capitalization$4.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.38
Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Receive TSRO News and Ratings via Email

Sign-up to receive the latest news and ratings for TSRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:TSRO
CUSIP88156910
Phone339-970-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$223.33 million
Book Value$4.58 per share

Profitability

Net Income$-496,120,000.00
Net Margins-295.67%

Miscellaneous

EmployeesN/A
Market Cap$4.13 billion
Next Earnings DateN/A
OptionableOptionable

TESARO (NASDAQ:TSRO) Frequently Asked Questions

What is TESARO's stock symbol?

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

How were TESARO's earnings last quarter?

TESARO Inc (NASDAQ:TSRO) announced its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($3.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.66) by $0.38. The biopharmaceutical company had revenue of $57.21 million for the quarter, compared to analyst estimates of $65.50 million. TESARO had a negative return on equity of 1,209.72% and a negative net margin of 295.67%. The company's quarterly revenue was up 94.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.82) earnings per share. View TESARO's Earnings History.

What price target have analysts set for TSRO?

21 brokerages have issued 12-month target prices for TESARO's stock. Their forecasts range from $25.00 to $128.00. On average, they anticipate TESARO's stock price to reach $72.2222 in the next year. View Analyst Price Targets for TESARO.

What is the consensus analysts' recommendation for TESARO?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TESARO in the last year. There are currently 16 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TESARO.

What are Wall Street analysts saying about TESARO stock?

Here are some recent quotes from research analysts about TESARO stock:
  • 1. Cantor Fitzgerald analysts commented, ": 12-month PT of $68 on shares of TSRO. Bloomberg reported last week that Tesaro was exploring a sale. We think that the company remains undervalued based on 1) PARP inhibitor potential in first-line ovarian cancer and 2) potential with its immuno-oncology platform (licensed from AnaptysBio, ANAB, OW, covered by Eliana Merle) that is beginning to shape up with data readouts. We also believe that it can take time for deals to emerge, so we think that this press article could be a way of garnering interest for the company beyond potentially initial interest. In the past, we think that this company had been a potential takeout interest from biopharmaceutical companies." (11/19/2018)
  • 2. According to Zacks Investment Research, "TESARO's drug, Zejula has performed well since its approval in early 2017, gaining lead in U.S. ovarian cancer market share in the PARP inhibitor segment. The drug also has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, collaborations with several large pharma companies for the development of Zejula generates a cash flow stream for TESARO and enables sharing of R&D costs. TESARO’s efforts for label expansion of Zejula are also encouraging. However, TESARO is heavily dependent on Zejula for growth, which concerns us. Meanwhile, competition in the PARP inhibitor segment is rising with two other approved drugs and several companies developing their candidates. TESARO’s shares have underperformed the industry so far this year. Loss estimates have widened ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (10/23/2018)

Has TESARO been receiving favorable news coverage?

Media headlines about TSRO stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TESARO earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days.

Who are some of TESARO's key competitors?

What other stocks do shareholders of TESARO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TESARO investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), Clovis Oncology (CLVS), Tesla (TSLA), Celgene (CELG), Biogen (BIIB), Exelixis (EXEL) and Intel (INTC).

Who are TESARO's key executives?

TESARO's management team includes the folowing people:
  • Mr. Leon O. Moulder Jr., Co-Founder, CEO & Director (Age 62)
  • Dr. Mary Lynne Hedley Ph.D., Co-Founder, Pres, COO & Director (Age 56)
  • Mr. Timothy R. Pearson, Exec. VP & CFO (Age 51)
  • Dr. Martin H. Huber Jr., Sr. VP & Chief Medical Officer (Age 59)
  • Mr. Orlando Oliveira, Sr. VP & GM of International (Age 43)

How big of a company is TESARO?

TESARO has a market capitalization of $0.00 and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis.

What is TESARO's official website?

The official website for TESARO is http://www.tesarobio.com.

How can I contact TESARO?

TESARO's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900.


MarketBeat Community Rating for TESARO (NASDAQ TSRO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  613 (Vote Outperform)
Underperform Votes:  469 (Vote Underperform)
Total Votes:  1,082
MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe TSRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Featured Article: Consumer Price Index (CPI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel